1,1'-Carbonyldiimidazole → 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester

HRID 896176ノート

反応式

HRID 896176 の反応式
C1N=CN([C:6](N2C=NC=C2)=[O:7])C=1.[CH2:13]([O:15][C:16](=[O:35])[C@H:17]([OH:34])[CH2:18][NH:19][C:20]1[CH:25]=[CH:24][C:23]([N:26]2[CH:31]=[CH:30][C:29](=[O:32])[CH2:28][CH2:27]2)=[C:22]([F:33])[CH:21]=1)[CH3:14]>C(#N)C>[CH2:13]([O:15][C:16]([CH:17]1[O:34][C:6](=[O:7])[N:19]([C:20]2[CH:25]=[CH:24][C:23]([N:26]3[CH:27]=[CH:28][C:29](=[O:32])[CH2:30][CH2:31]3)=[C:22]([F:33])[CH:21]=2)[CH2:18]1)=[O:35])[CH3:14]

参加物

4

反応物 2

HCID 682631,1'-CarbonyldiimidazoleHCID 684871023-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenylamino]-2(R)-hydroxypropionic acid ethyl ester

生成物 1

HCID 684890643-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester

試薬・触媒・溶媒 1

HCID 6342Acetonitrile溶媒

実験手順

CDI (162.0 mg, 1.0 mmol) is added with stirring to a solution of 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenylamino]-2(R)-hydroxypropionic acid ethyl ester (Step 5, 146.0 mg, 0.45 mmol) in acetonitrile (4.0 mL), and the mixture is stirred at room temperature overnight. Solvent is removed under vacuum, and the residue partitioned between EtOAc (30 mL) and aq. 3% citric acid (30 mL). The aqueous layer is extracted with EtOAc (2×30 mL), and the combined organic layers are washed with water and saline and dried (MgSO4). EtOAc is removed under vacuum to afford the crude 3-[3-fluoro-4-(4-oxo-3,4-dihydro-2H-pyridin-1-yl)phenyl]-2-oxo-5-oxazolidinecarboxylic acid ethyl ester which is used in the next step w/o further purification (MS (m/z): 349 [M+H]+). The ester intermediate is taken up in 2M methanolic ammonia (8.0 mL, 16.0 mmol), and the resulting solution heated in a closed vial at 60° C. for 1 h. Volatiles are removed under vacuum, and the crude material purified by silica gel chromatography (eluent: 2% MeOH in CH2Cl2) to afford the title compound (55.0 mg, 38% for two steps) as white crystals, MS for C15H14FN3O4 m/z 320 (M+H)+; 1H NMR (CD3CN): δ 2.51 (m, 2 H), 3.89 (m, 2 H), 4.05 (m, 1 H), 4.24 (dd, 1 H), 4.97 (m, 1 H), 5.03 (d, 1 H), 6.18 (br. s, 1 H), 6.72 (br. s, 1 H), 7.20-7.40 (m, 3 H), 7.57 (d, 1 H).

後処理

  1. customSolvent is removed under vacuum
  2. customthe residue partitioned between EtOAc (30 mL) and aq. 3% citric acid (30 mL)
  3. extractionThe aqueous layer is extracted with EtOAc (2×30 mL)
  4. washthe combined organic layers are washed with water and saline
  5. dry with materialdried (MgSO4)
  6. customEtOAc is removed under vacuum

出典と根拠

ORDレコード
ord-87fc1ad1aece455da5858e49d45b86e8
出典データセット
uspto-grants-2005_07
特許番号
US06919329B2

反応ノート

読み込み中…